Related Experiment Videos
[Osteoporosis after solid organs transplantation].
Rogério Cipriani1, Maria Lucia F Farias
1Serviço de Endocrinologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, RJ. rcipra@ig.com.br
Arquivos Brasileiros De Endocrinologia E Metabologia
|March 18, 2006
Summary
Post-transplant osteoporosis is common due to immunosuppressants and other factors. Bisphosphonates show promise for preventing and treating bone loss in transplant recipients.
Area of Science:
- Nephrology
- Immunology
- Endocrinology
- Orthopedics
Context:
- Osteoporosis frequently complicates solid organ transplantation (kidney, heart, liver, lung).
- Immunosuppressive drugs (glucocorticoids, cyclosporin A, tacrolimus) impair bone and mineral homeostasis.
- Transplant recipients often have pre-existing skeletal compromise.
Purpose:
- To review the pathogenesis of post-transplantation osteoporosis.
- To outline strategies for optimizing bone health before and after transplantation.
- To discuss therapeutic options for managing bone loss.
Summary:
- Common immunosuppressive regimens negatively impact bone health.
- Vitamin D insufficiency, secondary hyperparathyroidism, and hypogonadism contribute to osteoporosis.
- Pre-transplant assessment of bone mineral density, vitamin D, and gonadal status is recommended.
- Prophylaxis against bone loss is advised for all transplant patients.
- Bisphosphonates are identified as promising agents for prevention and treatment.
Impact:
- Highlights the significant risk of osteoporosis post-transplantation.
- Emphasizes the need for proactive bone health management in transplant candidates and recipients.
- Suggests bisphosphonates as a key therapeutic strategy for post-transplant bone disease.